SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-364960
Filing Date
2021-12-22
Accepted
2021-12-22 16:06:55
Documents
12
Period of Report
2021-12-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Document Format Files

Seq Description Document Type Size
1 8-K d265103d8k.htm   iXBRL 8-K 23831
  Complete submission text file 0001193125-21-364960.txt   145806

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA vir-20211216.xsd EX-101.SCH 2874
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE vir-20211216_lab.xml EX-101.LAB 18139
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vir-20211216_pre.xml EX-101.PRE 11397
6 EXTRACTED XBRL INSTANCE DOCUMENT d265103d8k_htm.xml XML 3362
Mailing Address 499 ILLINOIS STREET SUITE 500 SAN FRANCISCO CA 94158
Business Address 499 ILLINOIS STREET SUITE 500 SAN FRANCISCO CA 94158 415-906-4324
Vir Biotechnology, Inc. (Filer) CIK: 0001706431 (see all company filings)

IRS No.: 812730369 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39083 | Film No.: 211513295
SIC: 2836 Biological Products, (No Diagnostic Substances)